

ORASURE TECHNOLOGIES INC  
Form 8-K  
November 19, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): November 18, 2009**

**OraSure Technologies, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction

of Incorporation)

**001-16537**  
(Commission

File Number)

**36-4370966**  
(I.R.S. Employer

Identification No.)

Edgar Filing: ORASURE TECHNOLOGIES INC - Form 8-K

**220 East First Street**

**Bethlehem, Pennsylvania**  
(Address of Principal Executive Offices)

**Registrant's telephone number, including area code: 610-882-1820**

**18015-1360**  
(Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01 Entry Into a Material Definitive Agreement.**

On November 18, 2009, OraSure Technologies, Inc. (the Company ) entered into a Settlement Agreement, a License Agreement and certain other agreements in order to settle a patent infringement lawsuit filed against the Company by Inverness Medical Innovations, Inc. ( IMI ), Inverness Medical Switzerland GmbH and Church & Dwight, Co., Inc. On November 19, 2009, the Company issued a press release announcing the settlement and describing, among other things, the principal terms of the Settlement Agreement and License Agreement. A copy of this press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

**Item 7.01 Regulation FD Disclosure.**

On November 18, 2009, the Company issued a press release announcing its participation in a recent Blood Products Advisory Committee ( BPAC ) meeting and its plans to continue pursuing U.S. Food and Drug Administration ( FDA ) approval of an OraQuick<sup>®</sup> HIV over-the-counter test. A copy of this press release is attached as Exhibit 99.2 to this Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

**Exhibit**

<b>Number</b>	<b>Description</b>
99.1	Press Release, dated November 19, 2009, Announcing Settlement of Patent Infringement Litigation between the Company and Inverness Medical Innovations, Inc., Inverness Medical Switzerland GmbH and Church & Dwight, Co., Inc.
99.2	Press Release, dated November 18, 2009, announcing the Company's participation in a recent BPAC meeting and plans to continue pursuing FDA approval of an OraQuick <sup>®</sup> HIV OTC test.

**Signatures**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ORASURE TECHNOLOGIES, INC.

Date: November 19, 2009

By: /s/ JACK E. JERRETT  
**Jack E. Jerrett**  
**Senior Vice President, General Counsel and Secretary**

**Index to Exhibits**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release, dated November 19, 2009, Announcing Settlement of Patent Infringement Litigation between the Company and Inverness Medical Innovations, Inc., Inverness Medical Switzerland GmbH and Church & Dwight, Co., Inc.
99.2	Press Release, dated November 18, 2009, announcing the Company's participation in a recent BPAC meeting and plans to continue pursuing FDA approval of an OraQuick® HIV OTC test.